At cut-off, 46% of patients in chronic-phase CML (CML-CP) had a duration of exposure of 6 to 12 months and 18% of patients had a duration of exposure of more than 12 months.
Hindamishetkel oli 46% kroonilises faasis KML (KML- KF) patsientidest ravi kestnud 6... 12 kuud ja 18% patsientidest üle 12 kuu.